Apr. 24 at 11:24 PM
$GRCE
From a technical perspective, this chart is forming a bottom.
As a trader, I see the FDA CRL as constructive — the drug itself wasn’t rejected.
I feel for long-term holders, but for traders like me, this looks like a solid swing entry.
